3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Body Dysmorphic Disorders in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Booij, J; Denys, D; Figee, M; Planting, RS; Vulink, NC | 1 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Body Dysmorphic Disorders
Article | Year |
---|---|
Reduced striatal dopamine D2/3 receptor availability in Body Dysmorphic Disorder.
Topics: Adult; Benzamides; Body Dysmorphic Disorders; Case-Control Studies; Corpus Striatum; Dopamine Antagonists; Female; Humans; Image Processing, Computer-Assisted; Male; Pyrrolidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Young Adult | 2016 |